India, April 27 -- Oruka Therapeutics, Inc. (ORKA) on Monday reported positive interim results from its Phase 2a EVERLAST-A trial of ORKA-001 in moderate-to-severe plaque psoriasis. The company's shares rose more than 20% in pre-market trading.
In the study, 63.5% of patients treated with ORKA-001 achieved PASI 100 at Week 16, indicating complete skin clearance, with similar results seen on the Investigator's Global Assessment (IGA 0). Further, ORKA-001 was well tolerated, with no serious treatment-emergent adverse events reported.
Oruka said it plans to share longer-term data from the trial, including Week 28 efficacy and 52-week follow-up for some patients, in the second half of 2026. The company is also advancing its Phase 2b EVERLAST-...